He said that based on the results of the completed clinical trials of the vaccine among 150 volunteers over 60 years old, 94% of them were immune to coronavirus.
“I am sure that by the end of February the vaccine will be available to volunteers and residents of Russia over 60 years old within the framework of civil circulation,” Maksyutov said on the air of the Russia 24 TV channel.
According to him, this will be possible after the corresponding changes are made to the instructions for the drug.
At the same time, the decision to conduct clinical trials of the vaccine in children has not yet been made.
Maksyutov also said that EpiVacCorona has confirmed its effectiveness against the British strain of coronavirus.
On February 4, Vector completed clinical trials of the vaccine among the elderly.
Vektor expects that immunity to coronavirus after vaccination with EpiVacCorona will persist for a year.